News & perspective.
What we are reading, building and learning on the path to earlier diagnosis. Every external claim links to its source.
What your eyes give away before your memory does.
Eye movements shift measurably in mild cognitive impairment and early Alzheime’s, often before memory complaints. Tracking them needs no clinic, only a camera and the right tasks.
Read article →
Balance can be one of Parkinson’s earliest tells.
Subtle changes in balance and gait can precede a Parkinson’s diagnosis. Wearable and sensor research shows these signals are measurable, increasingly without a gait lab.
The 170 billion euro problem behind early detection
Neurodegenerative disease already costs Europe 170 billion euro a year, and most of it lands on families. Detection timing is part of that cost.
The face can register change before a person feels it.
Subtle shifts in facial movement and expression appear in dementia and Parkinson’s. A growing body of research suggests a camera can read these changes non-invasively.
Why one biomarker is never enough in neurodegeneration.
Neurodegenerative disease affects many systems at once, so single-signal tests miss things. Research increasingly points to combining biomarkers for a fuller, earlier picture.
Europe is ageing straight into the risk window.
Europe’s median age is the highest of any world region, and dementia risk climbs steeply with age. The demographics and the disease curve point the same way.
The hidden carbon cost of a brain scan.
Neurological diagnosis often means an energy-hungry MRI and a trip to hospital. Medical imaging carries a real carbon footprint that at-home assessment could help reduce.
What the German DiGA pathway means for digital diagnostics.
Germany was first to let statutory insurers reimburse certified digital health apps. Here is why that framework shapes our regulatory roadmap.
Voice is becoming a biomarker for cognition.
Subtle changes in speech can carry early signals of neurocognitive change, and the peer-reviewed evidence keeps growing.
Inside the 3.000-patient trial design.
Three cohorts, four hospital sites, eighteen months of data and a six-month follow-up, designed for evidence from day one.
A cross-border clinical network, by design.
Hospitals and academic groups across four countries give clinical validation regulatory weight from day one.